Exendin-4 Upregulates Adiponectin Level in Adipocytes via Sirt1/Foxo-1 Signaling Pathway.
PLoS One · 2017
Last updated 2026-05-28A study found that the GLP-1 drug exendin-4 increased levels of adiponectin, a hormone that helps the body use insulin better, in fat cells and living animals. The effect depended on the GLP-1 receptor and involved two proteins, Sirt1 and Foxo-1, which helped boost adiponectin production. Blocking Sirt1 or Foxo-1 reduced this effect.
AI summary of the abstract below.
| Journal | PLoS One, 2017 |
|---|---|
| Citations | 42 |
| Relative citation ratio | 1.82 |
| NIH percentile | 71 |
| Molecules | — |
| Conditions studied | Type 2 Diabetes, Obesity |
Abstract
Glucagon-like peptide-1 (GLP-1) receptor plays an essential role in regulating glucose metabolism. GLP-1 receptor agonists have been widely used for treating diabetes and other insulin resistance-related diseases. However, mechanisms underlying the anti-diabetic effects of GLP-1 receptor agonists remain largely unknown. In this study, we investigated the effects of GLP-1 agonist exendin-4 on the expression of adiponectin, an insulin sensitizing hormone. We found that exendin-4 increased the expression and secretion of adiponectin both in vitro and in vivo. Our data showed that exendin-4 upregulated adiponectin expression at both mRNA and protein levels in adipocytes and adipose tissues. The effects of exendin-4 on adiponectin expression were dependent on the GLP-1 receptor. We further demonstrated important roles of Sirt1 and transcriptional factor Foxo-1 in mediating the function of exendin-4 in regulating adiponectin expression. Suppression of Sirt1 or Foxo-1 expression significantly impaired exendin-4-induced adiponectin expression. Consistently, exendin-4 up-regulated Sirt1 and Foxo-1 expression in vivo. Our work is the first study demonstrating the role of Sirt1/Foxo-1 in regulating the regulatory function of a GLP-1 receptor agonist in adiponectin expression both in vitro and in vivo. The results provide important information for the mechanism underlying the function of GLP-1R on improving insulin resistance and related diseases.
Verbatim abstract via PubMed 28122026 ↗